Drugs / D5-0.9%NS
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03275792 | May 2020 → Apr 2021 | hemolytic-uremic syndrome | University of Calgary | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | D5-0.9%NS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03275792 ↗ |
| Route | Intravenous | “Infusion of 40 mL/kg of 0.9% normal saline (NS) IV over 60 minutes” NCT03275792 ↗ |